What is the plan of care for a patient with bilateral lower-leg ulcers, severe edema, heavy exudate, and yellow slough, with Ankle-Brachial Pressure Index (ABPI) values of 0.9 on the right and 0.7 on the left, who is on furosemide (Lasix) and has Congestive Heart Failure (CHF)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management Plan for Bilateral Lower-Leg Ulcers with CHF

This patient requires aggressive wound care with cautious compression therapy, optimization of CHF management with continued diuretic therapy, and careful monitoring for arterial insufficiency given the borderline-low ABPI values.

Immediate Assessment and Monitoring

Cardiovascular Status

  • Assess for signs of CHF decompensation including orthopnea, paroxysmal nocturnal dyspnea, jugular venous distention, S3 gallop, and pulmonary rales, as pedal edema with severe exudate may indicate worsening heart failure 1
  • Monitor daily weights, fluid intake/output, and vital signs (supine and standing) to assess volume status and adequacy of diuretic therapy 1
  • Check electrolytes and renal function regularly during diuretic therapy, as worsening renal function is associated with poor outcomes 1
  • Consider BNP or NT-proBNP measurement if CHF decompensation is suspected 1

Wound and Vascular Assessment

  • The right leg (ABPI 0.9) has adequate arterial perfusion and can tolerate standard compression therapy
  • The left leg (ABPI 0.7) indicates mild-to-moderate arterial insufficiency, requiring modified compression approach with reduced pressure (typically 15-25 mmHg rather than standard 30-40 mmHg)
  • Document wound size, depth, presence of yellow slough (indicating need for debridement), and signs of infection

Diuretic Management

Furosemide Optimization

  • Continue furosemide therapy as it is essential for managing CHF-related edema 1
  • If currently on oral furosemide and edema is severe, consider IV administration at least equivalent to the oral dose (or 20-40 mg IV if not currently on diuretics) 1
  • Monitor for diuretic response by tracking urine output, weight loss, and symptom improvement 1
  • If inadequate response occurs, consider dose escalation (can use up to 2.5× home dose) or adding a thiazide-type diuretic or spironolactone for synergistic effect 1

Critical Monitoring During Diuresis

  • Check electrolytes (especially potassium) and renal function within 1-2 weeks and regularly during active diuretic titration 1, 2
  • Watch for signs of over-diuresis including hypotension, worsening renal function, or electrolyte abnormalities 1
  • Avoid excessive diuresis as worsening renal function during hospitalization is associated with increased long-term mortality 1

Wound Care Protocol

Debridement and Cleansing

  • Remove yellow slough through sharp, enzymatic, or autolytic debridement to promote healing and reduce infection risk
  • Cleanse wounds with normal saline or appropriate wound cleanser

Dressing Selection

  • Use highly absorbent dressings (foam, alginate, or hydrofiber) to manage heavy exudate
  • Change dressings frequently enough to prevent maceration of surrounding skin
  • Consider antimicrobial dressings if signs of critical colonization or infection are present

Compression Therapy (Critical Component)

  • Right leg: Apply graduated compression (30-40 mmHg) using multi-layer bandaging or compression stockings once arterial adequacy is confirmed [@ABPI 0.9@]
  • Left leg: Apply REDUCED compression (15-25 mmHg maximum) due to ABPI of 0.7, which indicates arterial compromise
  • Monitor closely for signs of arterial insufficiency including increased pain, coolness, pallor, or wound deterioration
  • Reassess ABPI regularly and adjust compression accordingly

Systemic Optimization

CHF Management

  • Continue or optimize guideline-directed medical therapy including ACE inhibitors/ARBs and beta-blockers if blood pressure and renal function permit 1
  • Consider temporary reduction or discontinuation of ACE inhibitors/ARBs only if marked azotemia develops 1
  • Beta-blockers should generally be continued unless there is hemodynamic instability 1

Nutritional Support

  • Ensure adequate protein intake (1.0-1.5 g/kg/day) to support wound healing
  • Optimize micronutrients including zinc, vitamin C, and vitamin A if deficient
  • Implement sodium restriction (typically 2-3 g/day) to help manage fluid retention [@general medical knowledge@]

Follow-Up and Monitoring

Short-Term (1-2 Weeks)

  • Reassess wound healing progress, exudate levels, and signs of infection
  • Verify electrolytes and renal function after any diuretic adjustment 1, 2
  • Evaluate compression tolerance and adjust pressure as needed based on symptoms and ABPI

Medium-Term (Monthly)

  • Repeat ABPI measurements to detect any progression of arterial disease
  • Assess CHF compensation through clinical examination, weight trends, and possibly BNP levels 3
  • Consider vascular surgery referral if left leg ABPI deteriorates further or wounds fail to progress

Common Pitfalls to Avoid

  • Do NOT apply full compression to the left leg without considering the ABPI of 0.7, as this could cause tissue ischemia and wound deterioration
  • Do NOT discontinue diuretics due to concerns about wound healing; CHF-related edema will prevent healing 1
  • Do NOT ignore worsening renal function during aggressive diuresis, as this is associated with poor outcomes 1
  • Avoid NSAIDs as they can block diuretic effects and worsen renal function 2
  • Do NOT assume all edema is cardiac; investigate other causes including venous insufficiency, hypoalbuminemia, or medication effects 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Converting from Bumetanide to Torsemide

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.